Analyst Ratings January 26, 2026

Piper Sandler Stands by Overweight Rating on Nektar Therapeutics as Key Data Approaches

Analyst confidence centers on REZPEG induction data and upcoming maintenance topline readout expected in Q1 2026

By Marcus Reed NKTR
Piper Sandler Stands by Overweight Rating on Nektar Therapeutics as Key Data Approaches
NKTR

Piper Sandler has reiterated an Overweight rating on Nektar Therapeutics (NKTR) with a $105 price target, citing strong induction data for REZPEG and ample liquidity to support clinical programs. The firm flagged durability of response and regulatory endpoints as primary considerations ahead of maintenance topline results anticipated in the first quarter of 2026. Recent Phase 2b results for rezpegaldesleukin and subsequent analyst reactions have also placed Nektar in the spotlight.

Key Points

  • Piper Sandler reaffirmed an Overweight rating on Nektar Therapeutics (NKTR) with a $105 price target, noting REZPEGs strong induction data and sufficient liquidity (current ratio 4.24) to fund trials. - Sectors impacted: Biotechnology, Healthcare, Equity Markets.
  • Durability of response in maintenance data and regulatory endpoints (EASI-75 and IGA) are key near-term catalysts ahead of expected Q1 2026 topline results. - Sectors impacted: Regulatory affairs, Clinical development.
  • Phase 2b results for rezpegaldesleukin in alopecia areata narrowly missed the primary endpoint but showed a treatment effect more than double placebo; several analysts raised price targets or reiterated positive ratings. - Sectors impacted: Pharmaceutical R&D, Equity research.

Piper Sandler has reaffirmed its Overweight rating on Nektar Therapeutics (NASDAQ:NKTR) and set a price target of $105.00, reflecting a substantial premium to the recent share price of $36.40. The firm pointed to particularly strong induction data for REZPEG - Nektars experimental therapy for atopic dermatitis - as a key reason for sustained confidence as the company moves toward a maintenance topline readout expected in the first quarter of 2026.

The research note highlighted the companys financial position, noting a current ratio of 4.24 and concluding that Nektar has sufficient liquid resources to continue funding its clinical development programs. Piper Sandler emphasized that the durability of response in maintenance data will be a central focus when the results are released, with regulatory measures such as EASI-75 and Investigator Global Assessment (IGA) metrics included among the endpoints under scrutiny.

In its assessment, Piper Sandler referenced comparable outcomes as a baseline for success, stating that matching the efficacy profile reported for DUPIXENT - specifically 72% EASI-75 and 54% IGA 0/1 maintenance of response in DUPIXENTs studies - would constitute a clear positive result for REZPEG. The firm also addressed investor questions in detail, responding to 16 inquiries that examined trial design differences between maintenance and Phase 3 studies while maintaining a positive stance on the "substantial opportunity" the forthcoming data could represent.

Separate clinical news has kept Nektar in market focus. The companys Phase 2b trial for rezpegaldesleukin, an investigational treatment for alopecia areata, narrowly missed its primary endpoint; however, the trial data showed a treatment effect more than double that of placebo. That outcome prompted several analyst reactions and adjustments.

H.C. Wainwright increased its price target to $135, citing the potential importance of post-hoc analyses. Jefferies reiterated a Buy rating with a $121 price target, drawing attention to the trials favorable safety profile and the possibility the therapy could surpass existing treatment options. Oppenheimer raised its price target to $115, noting nominal statistical significance after excluding certain patient subsets from the analysis.

In addition to activity around Nektar, Terra Innovatum Global announced governance and compensation developments. The companys Remuneration Committee approved fixed annual compensation packages for Alessandro Petruzzi, Massimo Morichi, and Cesare Frepoli for the upcoming financial years, reflecting planned changes to director-level agreements.

Taken together, the analyst reiteration, ongoing clinical readouts, and corporate governance moves underline active strategic and operational developments for both companies referenced in the research notes and recent announcements.

Risks

  • Maintenance topline results expected in Q1 2026 may not demonstrate the durability of response that Piper Sandler cites as critical, affecting regulatory endpoints such as EASI-75 and IGA - Impacting: Biotechnology and Healthcare sectors.
  • The Phase 2b alopecia areata study for rezpegaldesleukin narrowly missed its primary endpoint, introducing uncertainty about the programs statistical conclusiveness despite a treatment effect exceeding placebo - Impacting: Clinical development and investor sentiment.
  • Comparisons to DUPIXENTs reported maintenance response (72% EASI-75 and 54% IGA 0/1) set a high efficacy benchmark; failure to meet similar outcomes would temper expectations for REZPEGs regulatory and commercial prospects - Impacting: Pharmaceutical competitive dynamics and market valuation.

More from Analyst Ratings

Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026 Needham Lifts Napco Security Price Target to $49 After Robust Q2 Results Feb 2, 2026 Evercore ISI Sticks with Outperform on Apple, Sets $330 Target Backed by App Store and Services Strength Feb 2, 2026 Deutsche Bank Says AppLovin Risk-Reward Looks Better After Google’s Project Genie Shock Feb 2, 2026